Search results for "End point"
showing 10 items of 14 documents
Progression-free survival as an end-point in clinical trials of biotherapeutic agents
2007
Abstract Progression-free survival (PFS), the time from registration or randomisation of a patient until objective disease progression or death, can be considered as an outcome for clinical research and also as a basis for regulatory approval. Current experience suggests that greater standardisation and consistency are needed for clinical trials utilising PFS endpoints. To this end, the Biotherapy Development Association (BDA) convened a breakout session on the topic of PFS during its Third Alpine Meeting held 14–16 March 2007. Representatives of the pharmaceutical industry, regulatory agencies, academia, and patient advocacy groups identified challenges, developed recommendations, and work…
Positron emission tomography in CNS drug discovery and drug monitoring.
2014
Molecular imaging methods such as positron emission tomography (PET) are increasingly involved in the development of new drugs. Using radioactive tracers as imaging probes, PET allows the determination of the pharmacokinetic and pharmacodynamic properties of a drug candidate, via recording target engagement, the pattern of distribution, and metabolism. Because of the noninvasive nature and quantitative end point obtainable by molecular imaging, it seems inherently suited for the examination of a pharmaceutical’s behavior in the brain. Molecular imaging, most especially PET, can therefore be a valuable tool in CNS drug research. In this Perspective, we present the basic principles of PET, th…
Free Energy, Enthalpy and Entropy from Implicit Solvent End-Point Simulations
2018
Free energy is the key quantity to describe the thermodynamics of biological systems. In this perspective we consider the calculation of free energy, enthalpy and entropy from end-point molecular dynamics simulations. Since the enthalpy may be calculated as the ensemble average over equilibrated simulation snapshots the difficulties related to free energy calculation are ultimately related to the calculation of the entropy of the system and in particular of the solvent entropy. In the last two decades implicit solvent models have been used to circumvent the problem and to take into account solvent entropy implicitly in the solvation terms. More recently outstanding advancement in both impli…
Arm end-point trajectories under normal and micro-gravity environments.
2001
Abstract The purpose of the present experiment was to study the way in which the CNS represents gravitational force during vertical arm pointing movements. Movements in upward and downward directions were executed by two cosmonauts in normal-gravity and weightlessness. Analyses focused upon finger kinematics in the sagittal plane. In normal-gravity, downward direction movements showed smaller curvatures and greater relative times to peak velocity ( AT MT ) when compared with upward direction movements. Data from the weightlessness experiments showed that whilst downward movements decreased their curvature during space flight, curvatures of upward movements changed slightly. Furthermore, AT …
The slowing down times of positrons emitted from selected β+ isotopes into metals
2012
Abstract We report the GEANT4 Monte Carlo simulations and the approximated calculations of the slowing down time (SDT) for positrons emitted from three β+ isotopes, i.e., 22Na, 68Ge/68Ga and 48V. The first two isotopes are commonly used in the positron annihilation spectroscopy. The results revealed that the SDT exhibits the nonsymmetrical distribution and its average value depends on the end point energy of the isotope, the density and atomic number of the implanted material. For metals the average SDT varies from 0.4 ps to a few ps. We argue that this can affect the analysis of the measured positron lifetime and should be considered in theoretical calculations. The SDT in selected gases w…
HADRON PHYSICS AT MAMI
2009
With the new stage of the MAMI accelerator, the physics program on hadron physics at MAMI will be extended up to an end point energy of 1.5 GeV. A few selected experiments on electro production are presented to show examples on nucleon structure and baryon resonance structure studies. The photo production program at MAMI was described in a separate talk in this conference.
Exclusive Semileptonic B and D Decays
1989
Interest in semileptonic (s.l.) bottom meson decays in the last few years has focused on the lepton energy end point spectrum. Theoretical models were needed for the description of the endpoint spectrum in order to be able to experimentally extract values for the ratio of KM matrix elements |Vbu/Vbc|. As approximately 90% of the total s.l. decay rate of bottom mesons is into the exclusive modes D and D* it was quite natural to try and model the endpoint spectrum by exclusive contributions. This approach was pioneered by GILMAN, ISGUR and WISE (GIW) in [1].
Sharp capacity estimates for annuli in weighted $$\mathbf {R}^n$$ R n and in metric spaces
2016
We obtain estimates for the nonlinear variational capacity of annuli in weighted $$\mathbf {R}^n$$ and in metric spaces. We introduce four different (pointwise) exponent sets, show that they all play fundamental roles for capacity estimates, and also demonstrate that whether an end point of an exponent set is attained or not is important. As a consequence of our estimates we obtain, for instance, criteria for points to have zero (resp. positive) capacity. Our discussion holds in rather general metric spaces, including Carnot groups and many manifolds, but it is just as relevant on weighted $$\mathbf {R}^n$$ . Indeed, to illustrate the sharpness of our estimates, we give several examples of …
Efficacy of C1 esterase inhibitor concentrate in treatment of cutaneous attacks of hereditary angioedema.
2015
BACKGROUND Although treatment with C1 esterase inhibitor (C1-INH) concentrate is well established for hereditary angioedema (HAE) attacks in general, data that assess its efficacy for cutaneous attack treatment are sparse. OBJECTIVE To assess efficacy of plasma-derived, nanofiltered C1-INH concentrate for cutaneous attack treatment by comparing treated attacks from the uncontrolled I.M.P.A.C.T.2 study with historical data for untreated attacks. METHODS Cutaneous attack data from patients with HAE who were treated for cutaneous edema with 20 IU/kg body weight C1-INH concentrate in the uncontrolled I.M.P.A.C.T.2 study (38 patients) were compared with data from untreated patients from an histo…
Predictors of mortality in COPD patients after hospitalization due to an exacerbation
2019
Aim: Identify factors related to mortality at 6 months after hospitalization by an acute COPD exacerbation (AECOPD). Method: We performed a 12-month prospective, observational study (July 2017-June 2018) that included COPD patients admitted by an AECOPD. Sociodemographic data, comorbidities, functional and clinical parameters were collected. Mortality at 6 months of admission was considered the end point. Results: 278 consecutive patients were enrolled, of whom 48 (16.2%) died during 6 months after AECOPD. Univariate analysis showed that age (p Conclusions: In COPD patients, Barthel Index, grade of dyspnea and previous hospitalizations are independent risk factors for mortality at 6 months,…